جست‌وجوی استاد و پژوهشگر

Steven Vollmerمشاهده پروفایل

استاد

• Evolutionary Genomics
• Ecological Genomics
• Coral Immunology
• +۴ مورد دیگر

Steven Vollmer serves as Director of the School of Environmental, Coastal, and Ocean Sustainability and Professor in the Department of Biological Sciences at Florida Atlantic University, having joined FAU in 2025 after 18 years as Professor of Marine and Environmental Science at Northeastern University where he directed the Bioinformatics program and served as Associate Director of the Marine Science Center. His postdoctoral research was conducted at the Smithsonian Tropical Research Institute in Panama. Education: B.S., Colorado State University, Fort Collins, CO M.S., California State University, Northridge, CA Ph.D., Harvard University, Boston, MA Dr. Vollmer is an evolutionary and ecological genomicist specializing in reef corals, with primary research focus on coral adaptation mechanisms against disease infection and thermal bleaching. His laboratory employs integrated field experiments, tank-based studies, and advanced genomic techniques to investigate coral immunity, host-pathogen dynamics, and microbial community interactions at molecular and organismal levels. This work directly informs marine conservation strategies and environmental sustainability initiatives for endangered coral ecosystems. Analysis of his 2021-2025 publications reveals a concentrated research trajectory centered on White Band Disease in Caribbean staghorn coral (Acropora cervicornis), leveraging genome-wide association studies, machine learning pathogen identification, and whole-genome assembly to uncover disease resistance mechanisms. His work bridges fundamental genomics with applied conservation, addressing urgent threats to coral reef resilience. Scientific Awards: National Academy of Science Kavli Fellow Advising and Grants: The source text does not specify doctoral advisees or grant funding details, though his research program implies active supervision of graduate students and secured external funding for genomic and disease ecology projects. Laboratory and Team: Dr. Vollmer leads a multidisciplinary research group integrating evolutionary genomics, bioinformatics, and marine ecology to study coral host-microbe-symbiont systems. His team conducts fieldwork across Caribbean and Indo-Pacific reefs while maintaining controlled tank experiments to simulate environmental stressors and disease challenges.

• RNA-targeted therapeutics
• Precision Medicine
• Chemoinformatics
• +۷ مورد دیگر

Matthew Disney is an Institute Professor and Chair of the Department of Chemistry at the University of Florida. His research program focuses on developing rational approaches to design selective therapeutics from genome sequence data, with particular emphasis on RNA-targeted drug discovery. He leads a highly productive research group that has pioneered innovative approaches in chemical biology and drug design. Dr. Disney's primary research interests include RNA-targeted therapeutics, precision medicine, chemoinformatics, RNA structure analysis, and drug design for neuromuscular and neurodegenerative diseases. His work bridges chemistry, biology, and medicine to develop novel treatments for conditions including muscular dystrophy, Alzheimer's, ALS, and difficult-to-treat cancers. His research has established that RNA can be effectively targeted with small molecules, challenging previous assumptions in the field. His recent publications demonstrate a strong focus on RNA-targeted therapeutics, with key advances including sequence-based drug design across the human transcriptome, development of RIBOTACs (ribonuclease-targeting chimeras) for catalytic RNA degradation, and creation of tools like Chem-CLIP for studying RNA-ligand interactions. The research spans from fundamental RNA structure studies to preclinical animal models, showing exceptional translational potential. The ACS 2022 Nobel Laureate Signature Award for Graduate Education in Chemistry (2021) The Raymond and Beverly Sackler International Prize in Chemistry (2019) BioFlorida's Weaver H. Gaines Entrepreneur of the Year (2018) NIH Director's Pioneer Award (2015) American Chemical Society's Eli Lilly Award in Biological Chemistry (2013) Dr. Disney's laboratory has trained numerous scientists who have gone on to successful careers in academia and industry. His research has been supported by substantial funding from the National Institutes of Health and other organizations. The Disney lab maintains strong collaborations across multiple disciplines, enhancing the impact of their RNA-targeted therapeutic approaches. The Disney group operates the Druggable Transcriptome Project and has developed the Inforna platform, which merges chemoinformatics and RNA structure to identify lead compounds targeting disease-associated RNAs. Their work on RIBOTACs represents a major advance in RNA-targeted therapeutics, enabling catalytic and substoichiometric degradation of disease-causing RNAs.

• Neuronal diversity and connectivity
• Mouse visual cortical circuit
• Brain circuitry
• +۷ مورد دیگر

Hongkui Zeng serves as Executive Vice President and Director of the Allen Institute for Brain Science, a position she assumed in 2020 after joining the institute in 2006 and leading its Structured Science Division from 2016-2020. She directs one of the world's leading neuroscience research organizations focused on creating comprehensive brain atlases and accelerating neuroscience discovery through open science principles. Dr. Zeng earned her Ph.D. in molecular and cell biology from Brandeis University studying circadian clock mechanisms in fruit flies, followed by postdoctoral research at MIT investigating hippocampus-dependent plasticity and learning. Her scientific journey has evolved toward systematic understanding of brain circuitry through large-scale, multidisciplinary approaches. Her research program centers on understanding neuronal diversity and connectivity in the mouse visual cortical circuit, employing a combined molecular, anatomical, and physiological approach. She has pioneered the development of multiple research platforms including single-cell transcriptomics, electrophysiology, 3D neuronal reconstruction, brain-wide connectivity mapping, and neuronal activity imaging to characterize neuronal cell types and their interconnections. Analysis of her recent publications (2023-2025) reveals a strong emphasis on creating multi-scale brain atlases that integrate transcriptomic, epigenomic, morphological, and connectivity data. Her work demonstrates increasing sophistication in mapping brain organization from molecular to circuit levels, with significant contributions to understanding healthy aging, cortical architecture, and cell-type-specific brain organization. Leading the BRAIN Initiative Cell Census Network Developing the Allen Mouse Brain Connectivity Atlas Creating comprehensive cell-type taxonomies Establishing standardized physiological survey methods As Director, she oversees major research programs, mentors scientific staff, and guides strategic direction for large-scale neuroscience projects that produce foundational resources for the global neuroscience community. Her leadership has positioned the Allen Institute at the forefront of systematic brain mapping initiatives that are transforming how we understand brain structure and function.

Jesse Rowleyمشاهده پروفایل

استادیار

• Platelet Biology
• Megakaryocyte Biology
• Hematology
• +۴ مورد دیگر

Jesse Rowley, PhD is a Principal Investigator at the University of Utah School of Medicine, Department of Internal Medicine. His research focuses on understanding how platelets and megakaryocytes influence human health and disease through integration of multi-omics approaches with traditional molecular, cellular, and in vivo methodologies. Dr. Rowley's educational background includes: PhD from The Johns Hopkins University BS from Brigham Young University Postdoctoral Fellowship at The Johns Hopkins University Postdoctoral Research Fellow at University of Utah Dr. Rowley's research interests center on platelet and megakaryocyte biology, with a focus on understanding the molecular mechanisms that govern platelet function in health and disease. His work integrates cutting-edge transcriptomic approaches with traditional molecular and cellular techniques to uncover new diagnostic and therapeutic avenues for platelet-related disorders. His laboratory has made significant contributions to understanding mitochondrial dynamics in platelets, the platelet transcriptome in various disease states, and developing innovative CRISPR-based approaches for studying platelet gene function. Analysis of Dr. Rowley's recent publications reveals a strong focus on platelet biology, particularly examining mitochondrial dynamics, transcriptomic changes in disease states, and innovative gene editing approaches. His work spans multiple disciplines including hematology, immunology, cardiovascular biology, and molecular genetics, with particular emphasis on how platelet dysfunction contributes to conditions like sepsis, thrombosis, autoimmune disorders, and viral infections including COVID-19. Dr. Rowley leads the Rowley Laboratory in Salt Lake City, Utah, which focuses on understanding platelet and megakaryocyte function through clinical discovery and advanced molecular, cellular, in vivo, and computational approaches. The lab has developed innovative techniques such as CRIMSON (CRISPR-edited Megakaryocytes for rapid Screening of platelet gene functiON) for studying platelet gene function.

• Genetic Epidemiology
• Pelvic Floor Disorders
• Food Allergies
• +۴ مورد دیگر

Kristina Lisa Allen-Brady is a Research Assistant Professor at the University of Utah School of Medicine , affiliated with the Division of Genetic Epidemiology within the Department of Internal Medicine. She also holds an adjunct position in the Department of Family & Preventive Medicine. Her academic work focuses on identifying genetic links in chronic diseases through epidemiological and molecular approaches. Education: PhD, MSPH, and MPT degrees from the University of Utah Professional Roles: Licensed physical therapist in Utah, member of American Society of Human Genetics and International Society of Genetic Epidemiology, IRB member Allen-Brady's research spans genetic epidemiology of pelvic floor disorders , food allergies , autism , and cancer , with a focus on genomic data analysis and transcriptomic profiling . She has contributed to large-scale studies on familial clustering of conditions like primary ovarian insufficiency , endometriosis , and diverticulitis , often employing genome-wide association studies (GWAS) and linkage analysis . Her collaborations with multidisciplinary teams highlight her expertise in biomedical informatics and statistical genetics . Her recent publications (2024-2025) demonstrate a strong emphasis on genetic risk factors for allergic disorders , gynecological conditions , and neurodegenerative diseases . Notable trends include investigating X chromosome mediation in Alzheimer's disease , immune-gene interactions in eosinophilic esophagitis , and polymorphism-disease associations (e.g., ZFAT , fibulin-5 genes). Allen-Brady's work is supported by active participation in academic societies and institutional review processes. She frequently collaborates with research teams across genetic epidemiology , gynecology , and public health domains.

William H. Majorosمشاهده پروفایل

استادیار

• Statistical Genetics
• Functional Genomics
• Bioinformatics
• +۵ مورد دیگر

William H. Majoros, Ph.D., serves as an Assistant Professor of Biostatistics and Bioinformatics at Duke University with key affiliations in the Division of Integrative Genomics, Duke Center for Statistical Genetics and Genomics, and Center for Combinatorial Gene Regulation. His educational background includes: Ph.D., Duke University (2017) Dr. Majoros specializes in developing computational frameworks for genomic regulation analysis, with core expertise in statistical genetics, non-coding DNA function, and high-throughput functional genomics. His research integrates Bayesian statistics with experimental genomics to decode gene regulatory mechanisms, particularly focusing on combinatorial effects of non-coding variants in disease contexts. Analysis of his 2018-2025 publications reveals consistent methodological innovation in allele-specific expression modeling, CRISPR screen analysis, and non-coding variant interpretation, with strong translational applications in rare genetic diseases and complex disorders. His research program is supported by major NIH funding including: Computational Methods for Investigating the Genetics of Gene Regulation (NIGMS, 2023-2028) Design and prioritization of systematic genome perturbations (NHGRI, 2021-2026) High-Throughput Functional Annotation of Regulatory Elements (NHGRI, 2021-2026) Beyond GWAS: Functional Genomics for Schizophrenia (NIMH, 2021-2026) Duke FUNCTION Center for combinatorial noncoding disease causes (NHGRI, 2020-2025) He actively mentors through COMPSCI/BIOSTAT research independent studies and teaches graduate courses including Graphical Models for Biological Data and Computational Sequence Biology, advancing training in statistical genomics methodologies.

Xiangdong William Yangمشاهده پروفایل

استاد

• Huntington's Disease
• Neuroscience
• Genetics
• +۶ مورد دیگر

Dr. Xiangdong William Yang is a Professor in Residence in the Department of Psychiatry & Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles. He is also a member of the Center for Neurobehavioral Genetics at Semel Institute for Neuroscience & Human Behaviors and the Brain Research Institute at UCLA. Dr. Yang serves as a regular member at the NIH's Cell Death in Neurodegeneration Study Section and is a Scientific Advisory Board member of the Hereditary Disease Foundation. Dr. Yang's educational background includes: Combined M.S. and B.S. degrees with summa cum laude from Molecular Biophysics & Biochemistry Department at Yale University (1991) Ph.D. in Molecular Genetics and Neuroscience from Rockefeller University (1998) M.D. from Weill Medical College of Cornell University (2000) Medicine Internship at New York-Presbyterian Hospital (2001) His primary research focuses on Huntington's disease pathogenesis, where he investigates cellular and molecular mechanisms of neurodegeneration. Dr. Yang's laboratory pioneered the BAC transgenic technology for modeling human diseases and developed the innovative MORF (MOnonucleotide Repeat Frameshift) methodology for sparse cell labeling to reveal brain-wide neural circuitry. His work spans genetic mechanisms of CAG repeat expansion, basal ganglia circuitry, microglial responses in neurodegeneration, and molecular pathways underlying selective neuronal vulnerability. Dr. Yang's recent publications demonstrate a strong emphasis on Huntington's disease mechanisms, particularly examining CAG repeat expansion dynamics, neuronal vulnerability patterns, and potential therapeutic approaches. His work increasingly incorporates multi-omics approaches including epigenetics, transcriptomics, and advanced imaging to uncover the complex interplay between genetic mutations and cellular dysfunction. Recent publications also show expansion into Alzheimer's disease research, particularly regarding microglial function and amyloid pathology. Dr. Yang has received numerous prestigious awards recognizing his contributions to neuroscience: The Terry Semel Chair in Alzheimer's Disease Research and Treatment, UCLA (2019) Elected Member, American Society for Clinical Investigation (2017) Leslie Gehry Brenner Prize for Innovation in Science, Hereditary Disease Foundation (2014) Center for Excellence in Education Outstanding Alumni in STEM and Business (2013) The Carol Moss Spivak Scholar in Neuroscience, UCLA (2011-2016) McKnight Neuroscience of Brain Disorders Award (2009-2012) As a principal investigator, Dr. Yang has mentored numerous graduate students and postdoctoral fellows in neuroscience research. His laboratory has been consistently supported by major grants from the NIH, Hereditary Disease Foundation, and other organizations focused on neurodegenerative diseases. Dr. Yang has served on the NIH's Cell Death in Neurodegeneration Study Section, evaluating grant proposals in his field of expertise. His research has directly contributed to preclinical development of therapeutic approaches for Huntington's disease. Dr. Yang leads a vibrant research laboratory at the Gonda Neuroscience & Genetics Research Center at UCLA. His team has developed innovative methodologies including the MORF sparse cell labeling technique for mapping brain circuitry. The lab collaborates extensively with other neuroscience researchers at UCLA and internationally, contributing to large consortia studying neurodegenerative diseases. Current research focuses on uncovering the molecular and circuit-level mechanisms of Huntington's disease with the goal of identifying therapeutic targets.

Marilyn C Cornelisمشاهده پروفایل

دانشیار

• Epidemiology
• Genomics
• Metabolomics
• +۵ مورد دیگر

Marilyn C Cornelis is an Associate Professor at Northwestern University's Feinberg School of Medicine , affiliated with the Department of Preventive Medicine (Epidemiology and Behavioral Medicine subprograms). Her research integrates systems epidemiology with genomics and metabolomics to explore the health impacts of coffee consumption, including its dual roles in cardiovascular disease, type II diabetes, and Parkinson’s disease. Her work has identified genetic variants linked to caffeine metabolism and psychoactive effects, and she advocates for personalized dietary recommendations based on genetic markers. Key publications include studies in Nature Communications , Nature Genetics , and JAMA Internal Medicine , reflecting her focus on cardiovascular health , genetic epidemiology , and precision nutrition . She is supported by grants such as the American Diabetes Association Grant 7-13-JF-15 and contributes to major initiatives like the NIH’s Nutrition for Precision Health Study (2025). Her research reveals complex interactions between coffee components, caffeine metabolism, and health outcomes, emphasizing individual variability.

Grant Morahanمشاهده پروفایل

استاد

• Genetics of Complex Diseases
• Type 1 Diabetes
• Systems Genetics
• +۴ مورد دیگر

Professor Grant Morahan is a leading researcher in the genetics of complex diseases, currently serving as Director of the Centre for Diabetes Research at the University of Western Australia and the Western Australian Institute for Medical Research at Royal Perth Hospital. He received his BSc(Hons) and PhD in immunogenetics from the University of Melbourne, following postdoctoral work as a Fogarty International Fellow at the Scripps Clinic. His career spans leadership roles at the Walter and Eliza Hall Institute and international collaborations through the Type I Diabetes Genetics Consortium and the Complex Trait Consortium. Education: BSc(Hons) from La Trobe University, PhD from University of Melbourne Key Appointments: Inaugural Diabetes Research Foundation Professor (2005), Director of Centre for Diabetes Research Research Focus: Genetics of type 1 diabetes, cardiovascular disease, immunological tolerance, and gene-environment interactions His scientific contributions include over 100 publications in top journals like Nature , Science , and Lancet , with recent work focusing on N-glycosylation mechanisms in diabetes, SEC61B-regulated platelet hyperreactivity, and genetic risk scores for diabetes complications. He has pioneered the use of genetically diverse mouse models to study disease variability. Scientific Awards: Faculty of 1000 member, Founding President of Immunology Group of Victoria, Australasian Society for Immunology Councillor Entrepreneurial Roles: Co-founder of Geniad (genetic resource-based pharmaceutical services) and GordianTec Pty Ltd (diagnostic technologies) His translational research includes patent filings for diabetes and cancer diagnostics through GordianTec, emphasizing improved patient management and disease outcomes. His work bridges fundamental genetic discoveries with clinical applications through active collaborations across immunology, endocrinology, and cardiovascular disciplines.

• Systems Biology
• Genomics
• CRISPR Technology
• +۱۲ مورد دیگر

Jonathan Weissman is a Professor in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco (UCSF), where he leads a highly influential research group at the forefront of systems biology, genomics, and genetic engineering. His work spans molecular pharmacology, synthetic biology, and cellular systems, with a focus on developing and applying cutting-edge technologies such as CRISPR, ribosome profiling, and Perturb-seq to interrogate gene function and regulation at scale. His research interests are centered on understanding the principles of gene expression, protein homeostasis, and cellular responses to stress. He has pioneered methods for genome-wide functional screening, translational regulation analysis, and single-cell genomics. His lab has developed tools for CRISPR interference (CRISPRi), ribosome profiling, and high-content genetic interaction mapping, which have been widely adopted in the scientific community. These approaches enable systematic dissection of complex biological processes, including protein folding, mitochondrial function, and immune cell regulation. The recent publications reflect a strong emphasis on single-cell resolution studies, in vivo screening, and the functional annotation of non-canonical genomic elements. Themes include CRISPR-based perturbation screens, spatial and temporal modeling of molecular systems, immune checkpoint regulation in cancer, and the role of non-coding RNAs in cell fate decisions. His work increasingly integrates multi-omics approaches to map regulatory networks with high precision. Dr. Weissman has mentored numerous students and postdoctoral researchers, many of whom have become independent investigators. His group collaborates extensively across disciplines and institutions, contributing to large-scale initiatives such as the Human Cell Atlas. He has not received any explicitly named scientific awards in the provided text, but his publication record in top-tier journals underscores his scientific impact. He leads a dynamic research laboratory focused on developing and applying scalable technologies for functional genomics. The lab emphasizes innovation in experimental design, computational analysis, and the translation of basic discoveries into biomedical applications, particularly in cancer and neurodegenerative diseases.

Guido Reifenbergerمشاهده پروفایل

استاد

• Molecular Neurooncology
• Genetic Aberrations
• Epigenetics
• +۳ مورد دیگر

Professor Guido Reifenberger is the Director of the Institute of Neuropathology at Heinrich Heine University Düsseldorf. He specializes in molecular neurooncology, focusing on genetic and epigenetic aberrations in primary brain tumors including gliomas, meningiomas, medulloblastomas, CNS lymphomas, and brain metastases. Director of the Institute of Neuropathology Member of the German Glioma Network Contributor to WHO CNS tumor classification Leader in establishing the CNS tumor tissue bank Düsseldorf His research integrates genome-wide and transcriptome-wide profiling to study tumor suppressor genes, proto-oncogenes, and non-coding RNA alterations. He has pioneered translational research linking genomic findings to clinical diagnostics through the German Cancer Consortium (DKTK). Key projects include: BMBF SysGlio Consortium (systems biology of glioma progression) Brain Tumor Funders Collaborative (glioblastoma survival mechanisms) DKTK non-coding mutation studies German Cancer Aid initiatives on meningiomas and brain metastases Publications reveal a focus on glioma molecular genetics, therapy resistance mechanisms, epigenetic alterations, and diagnostic implementation. His work has significantly influenced glioblastoma classification and treatment stratification. He collaborates with the Department of Neurosurgery at University Hospital Düsseldorf to maintain one of the world's largest brain tumor tissue banks, facilitating research on tumor heterogeneity and personalized treatment strategies.

• Plant Stress Tolerance
• Molecular Genetics
• Plant Genomics
• +۳ مورد دیگر

Alessandra Ruggiero is a Researcher at the Institute of Biosciences and BioResources (IBBR-CNR) , Portici Branch, Italy. She holds a PhD in Insect Science and Biotechnology from the University of Insubria and a Master’s in Biology from the University of Naples 'Federico II'. Her research focuses on plant responses to abiotic stresses (salinity, drought), molecular genetics, and genomics of stress tolerance in crops like tomato and pepper. Education : PhD (2011), University of Insubria; MS Biology (2007), University of Naples Awards : Cover features in Circulation Research (2016, 2014); SIGA 2014 Poster Award Her work spans stress signaling pathways (ABA, TOR), transcriptomic analysis , and bioresource characterization . Recent studies include electromagnetic water effects on potato , drought-tolerant tomato screening , and pepper ABA signaling mechanisms . She has contributed to tomato diversity atlases and phenylpropanoid biosynthesis research. Teaching activities include seminars on plant stress responses and mentorship roles in molecular biology training programs. Current affiliations: IBBR-CNR, Portici . Collaborations include University of Naples 'Federico II' and international consortia like the TRADITOM Horizon 2020 project. Technical expertise in molecular cloning , RNA-Seq analysis , and transformation techniques across plant and animal systems.

• Nephrology
• Pharmacogenomics
• Kidney Transplantation
• +۳ مورد دیگر

Dr. Casey Dorr is an Associate Professor in the Department of Medicine, Division of Nephrology and Hypertension at the University of Minnesota. Their primary research investigates pharmacogenomics, kidney transplantation outcomes, and interactions between immunosuppressive drugs and the gut microbiome. They specialize in genetic determinants of drug metabolism (e.g., tacrolimus, mycophenolate) and microbial influences on pharmacotherapy. Research interests span: Pharmacogenomics : Genetic variants affecting immunosuppressant dosing and toxicity. Microbiome Interactions : Gut microbiota's role in drug enterohepatic recirculation. Transplantation Science : Biomarkers for graft survival and rejection in diverse populations. Genomic Technologies : CRISPR models, spatial transcriptomics, and polygenic risk scores. Recent publications (2023–2025) demonstrate a focus on precision medicine in nephrology, with recurring themes of microbial metabolism of immunosuppressants, genetic predictors of drug response, and health disparities in transplant outcomes. Studies utilize longitudinal cohorts, next-generation sequencing, and digital spatial profiling to advance personalized therapeutic strategies.

• Medical Genetics
• Human Disease Genes
• Pulmonary Arterial Hypertension
• +۵ مورد دیگر

Professor Richard Trembath is a Professor of Medical Genetics at King's College London (KCL), where he has served since 2005. Previously, he held the Foundation Chair of Medical Genetics at the University of Leicester from 1992. Trembath has held significant leadership positions including Head of Division of Genetics & Molecular Medicine (2008-11), founding Director of the KCL/GSTT NIHR Comprehensive Biomedical Research Centre, Senior Vice President (SVP) for Life Sciences & Health, and Executive Director of King's Health Partners Academic Health Science Centre. Prior to joining King's, he was Vice-Principal for Health at Queen Mary University London and Executive Dean of Barts and The London School of Medicine and Dentistry. His educational background includes medical training at Guy's Hospital Medical School followed by postgraduate training at the Institute of Child Health. Trembath is a Fellow of the Academy of Medical Sciences and King's College London. Richard Trembath's research focuses on identifying human disease genes using established and emerging technologies. His work spans rare medical conditions such as pulmonary arterial hypertension to more common disorders including psoriasis, atopic dermatitis, and acne. He co-founded the East London Genes and Health project, one of the world's largest community-based genetics studies funded by the Wellcome Trust, aimed at improving health among people of Pakistani and Bangladeshi heritage in East London. His research employs genome-wide association studies, whole-genome sequencing, and polygenic risk score analysis to understand the genetic architecture of various diseases. His recent publications demonstrate a strong focus on pulmonary arterial hypertension, psoriasis, and the genetic factors influencing responses to diseases like COVID-19. His work often involves large international consortia and emphasizes population-specific genetic research, particularly with British South Asian populations. Fellow of the Academy of Medical Sciences Fellow of King's College London Professor Trembath has led major research initiatives including the East London Genes and Health project, which has enrolled over 50,000 participants. His work has been supported by major funding bodies including the Wellcome Trust and the National Institute for Health Research. He has played a key leadership role in establishing research infrastructure at King's College London, drawing together the university with major NHS Trusts to accelerate health innovation. His laboratory has made significant contributions to understanding the genetic basis of pulmonary arterial hypertension, identifying rare variants in genes like KDR, FBLN2, and PDGFD. His team has also pioneered research on polygenic risk scores in British Pakistani and Bangladeshi populations, demonstrating how genetic risk prediction can be adapted for diverse ethnic groups.

• Glaucoma
• Genetics
• Optic Nerve
• +۵ مورد دیگر

Sjoerd Driessen is a Researcher in the Department of Ophthalmology at Erasmus MC, a leading medical center in the Netherlands. His work focuses on the genetic and clinical aspects of glaucoma, with particular emphasis on population differences and advanced imaging techniques. Dr. Driessen's research spans multiple interconnected domains within ophthalmology and genetics. His primary focus is on glaucoma, examining genetic factors through genome-wide association studies and polygenic risk scores. He investigates intraocular pressure dynamics, optic nerve pathology, and applies optical coherence tomography for early detection. His work often addresses population-specific differences, particularly between African and European descent groups. He also explores the intersection of neural network technology with ophthalmic imaging, developing computational approaches for feature extraction from medical scans. Analysis of Dr. Driessen's publication record reveals a strong trajectory in glaucoma genetics research with increasing methodological sophistication. His recent work demonstrates progression from clinical characterization of glaucoma across populations to more complex genetic analyses and computational approaches. The publications show growing international collaboration, with studies incorporating data from diverse global populations. His research increasingly integrates multiple methodologies, combining genetic analysis with advanced imaging techniques and computational approaches to tackle glaucoma from multiple angles. Dr. Driessen actively collaborates with major research consortia including the International Glaucoma Genetics Consortium and has contributed to significant studies using large datasets like the UK Biobank and Million Veteran Program. His research has gained attention in the scientific community, with several publications being highlighted in news outlets and receiving substantial readership on academic platforms.